RRM2 and lymphoma: The results revealed that RRM2 expression was significantly increased in most cancer groups, including bladder, brain, breast, cervical, colorectal, esophageal, gastric, head and neck, kidney, liver, lung, lymphoma, melanoma, ovarian, pancreatic, prostate, and sarcoma cancers.